Research programme: liver targeted prodrugs - Metabasis TherapeuticsAlternative Names: Research programme: Hepatitis B prodrugs - Metabasis Therapeutics
Latest Information Update: 05 Apr 2007
At a glance
- Originator Metabasis Therapeutics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 05 Apr 2007 Discontinued - Preclinical for Hepatitis B in USA (unspecified route)
- 10 Sep 2001 New profile
- 10 Sep 2001 Preclinical development for Hepatitis B in USA (Unknown route)